Treatment Centers and Clinical Trials
You can restrict your search to only Treatment Centers or only Clinical Trials by checking the Treatment Center or Clinical Trial checkbox under TYPE. Use the Zoom-In (+ sign on the lower right of the map) to enlarge the map area to find your preferred location. To search for a Treatment Center or Clinical Trial, click on the red map pin for the name of the facility. Click on the name of the facility for more details.
Location
Treatments/Services
Type
OhioHealth Physician Group - Hematology/Oncology
ROCHESTER SKIN LYMPHOMA MEDICAL GROUP, PLLC
Rush University Medical Center
The University of Kansas Hospital
The Warren Alpert Medical School of Brown University, Department of Dermatology
Fred Hutchinson Cancer Center
Tulane University School of Medicine
University Dermatology Consultants, Inc.
University Hospitals of Cleveland
University of Alabama Medical Center
University of California, San Francisco
University of Iowa Hospitals & Clinics
University of North Carolina Medical Center
University of Pittsburgh Medical Center
University of Rochester - Wilmot Cancer Institute
University of Texas Southwestern Medical Center
University of Virginia-Emily Couric Clinical Cancer Center
University of Wisconsin - Madison
Vanderbilt University Medical Center
Atrium Health Wake Forest Baptist
Winship Cancer Institute - Emory University
Mayo Clinic - Arizona Campus
Cleveland Clinic
Clinical Cancer Center, Froedtert Hospital
Saint Louis University Cancer Center
Washington University Medical Center - Siteman Cancer Center
The Dermatology Clinic at University of Minnesota
Henry Ford Hospital - Cutaneous Lymphoma Program
University of Michigan Medical Center
Northwestern Medicine
University of Chicago
Yale University School of Medicine
Penn Cutaneous Lymphoma Program
Jefferson Cutaneous Lymphoma Clinic
Boston Medical Center - Cutaneous Oncology Program
Center for Cutaneous Oncology at Dana Farber/Brigham and Women's Cancer Center
Beth Israel Medical Center
Massachusetts General Hospital Cancer Center
Virginia Commonwealth University Medical Center
INOVA Melanoma and Skin Oncology Center
Dartmouth-Hitchcock Norris Cotton Cancer Center
Columbia University Irving Medical Center - Cutaneous Lymphoma Center
NYU Grossman School of Medicine
University of Texas MD Anderson Cancer Center
Moffitt Cancer Center
Cleveland Clinic - Indian River Hospital
Miami Cancer Institute BHSF
Levine Cancer Institute
Duke Cutaneous T-Cell Lymphoma Clinic and Research Center
UCHealth - University of Colorado Cancer Center - Anschutz
Huntsman Cancer Institute
Stanford Medical Center (Multidisciplinary Cutaneous Lymphoma Clinic)
Oregon Health & Science University (OHSU)
MUSC Cutaneous Lymphoma Clinic
Johns Hopkins Dermatology
OU Physicians
City of Hope National Medical Center
Chao Family Comprehensive Cancer Center
Mayo Clinic - Florida
Fondazione IRCCS Ca' Granda
IU Simon Cancer Center
Peter MacCallum Cancer Centre
Westmead Hospital - University of Sydney
Medical University of Graz
Medical University of Vienna
Hôtel-Dieu - CHU de Nantes
Helsinki University Hospital
Hospital Dresden-Friedrichstadt
Charité University of Medicine Berlin - Skin Cancer Center
Skin Cancer Center - HELIOS Klinikum Krefeld
Rabin Medical Center
Rambam Medical Center
Spedali Civili di Brescia
Cutaneous Lymphoma Multidisciplinary Clinic - Lisbon
Friedrich Schiller University - Hospital Jena
University Medical Centre - Mannheim
University of Essen - Department of Dermatology
Semmelweis Medical School
Hospital Universitario 12 de Octubre
Cutaneous Lymphoma Clinic - Kimberly and Eric J. Waldman Dept of Dermatology
University Hospital Zurich - Department of Dermatology
Memorial Sloan Kettering Cancer Center
John Theurer Cancer Center at HUMC
Emil P. Bisaccia, MD, Center for Photopheresis at Morristown Medical Center
Johann Wolfgang Goethe-University Frankfurt
OSU Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center
St. Thomas Hospital - St Johns Department of Dermatology
UAMS Cancer Center
University Dermatology and Skin Cancer Center
Lacutamab - TELLOMAK Study
An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of lacutamab (IPH4102) alone or in combination with chemotherapy in patients with advanced t-cell lymphoma
Clinical Trial Name: IPH4102-201 / TELLOMAK study
Clinical Trial Description:
TTI-621 - Study
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Brief Summary
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB MF and SS
Brief Summary:
Pembrolizumab - Stage IB-IV Mycosis Fungoides
Brief Summary:
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
Website: https://clinicaltrials.gov/ct2/show/NCT03695471?term=mc1788&draw=2&rank=1
PRIMARY OBJECTIVE:
Mogamulizumab Q4week Dosing
Brief Summary:
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Dose-Escalation Trial Evaluating CPI-818
Brief Summary:
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug. This trial is composed of dose escalation and dose expansion cohorts.
Duvelisib + Nivolumab for the Treatment of MF and SS
Brief Summary:
Extracorporeal Photopheresis in Sezary Syndrome (ECP)
Brief Summary:
Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Brief Summary:
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTC
Brief Summary:
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.